LY2940094 tartrate

Cat. No.:	HY-114452A
CAS No.:	1307245-87-9
Molecular Formula:	$C_{26}H_{29}ClF_2N_4O_8S$
Molecular Weight:	631.05
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models[1].
IC_{50} & Target	Ki: 0.105 nM (NOP receptor)[1] Kb: 0.166 nM (NOP receptor)[1]
In Vivo	LY2940094 (3, 10, or 30 mg/kg; orally daily for 4 days) dose-dependently reduces homecage ethanol self-administration in Indiana Alcohol-Preferring (P) and Marchigian Sardinian Alcohol-Preferring (msP) rats, without affecting food/water intake or locomotor activity[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Alcohol-Preferring (P) rats (250-320 g); Male Marchigian Sardinian Alcohol-Preferring (msP) rats (400-450 g)[1]
Dosage:	3, 10, or 30 mg/kg
Administration:	P.o.; daily for 4 days
Result:	Reduced homecage ethanol self-administration.

REFERENCES

[1]. Rorick-Kehn LM, et al. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcohol Clin Exp Res. 2016 May;40(5):945-54.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA